CGRP may play a causative role in migraine
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
CGRP may play a causative role in migraine. / Lassen, L H; Haderslev, P A; Jacobsen, V B; Iversen, Helle Klingenberg; Sperling, B; Olesen, J.
In: Cephalalgia : an international journal of headache, Vol. 22, No. 1, 02.2002, p. 54-61.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - CGRP may play a causative role in migraine
AU - Lassen, L H
AU - Haderslev, P A
AU - Jacobsen, V B
AU - Iversen, Helle Klingenberg
AU - Sperling, B
AU - Olesen, J
PY - 2002/2
Y1 - 2002/2
N2 - Calcitonin gene-related peptide (CGRP) has been detected in increased amounts in external jugular venous blood during migraine attacks. However, it is unknown whether this is secondary to migraine or whether CGRP may cause headache. In a double-blind crossover study, the effect of human alphaCGRP (2 microg/min) or placebo infused intravenously for 20 min was studied in 12 patients suffering from migraine without aura. Headache intensity was scored on a scale from 0 to 10. Two patients were excluded due to severe hypotension and one because she had an infection. In the first hour median peak headache score was 1.0 in the halphaCGRP group vs. 0 in the placebo group (P < 0.01). During the following 11 h all patients experienced headaches after halphaCGRP vs. one patient after placebo (P = 0.0004). The median maximal headache score was 4 after CGRP and 0 after placebo (P = 0.006). In three patients after halphaCGRP, but in no patients after placebo, the delayed headache fulfilled the IHS criteria for migraine without aura. As intravenous administration of halphaCGRP causes headache and migraine in migraineurs, our study suggests that the increase in CGRP observed during spontaneous migraine attacks may play a causative role.
AB - Calcitonin gene-related peptide (CGRP) has been detected in increased amounts in external jugular venous blood during migraine attacks. However, it is unknown whether this is secondary to migraine or whether CGRP may cause headache. In a double-blind crossover study, the effect of human alphaCGRP (2 microg/min) or placebo infused intravenously for 20 min was studied in 12 patients suffering from migraine without aura. Headache intensity was scored on a scale from 0 to 10. Two patients were excluded due to severe hypotension and one because she had an infection. In the first hour median peak headache score was 1.0 in the halphaCGRP group vs. 0 in the placebo group (P < 0.01). During the following 11 h all patients experienced headaches after halphaCGRP vs. one patient after placebo (P = 0.0004). The median maximal headache score was 4 after CGRP and 0 after placebo (P = 0.006). In three patients after halphaCGRP, but in no patients after placebo, the delayed headache fulfilled the IHS criteria for migraine without aura. As intravenous administration of halphaCGRP causes headache and migraine in migraineurs, our study suggests that the increase in CGRP observed during spontaneous migraine attacks may play a causative role.
KW - Adult
KW - Blood Flow Velocity
KW - Brain
KW - Calcitonin Gene-Related Peptide
KW - Double-Blind Method
KW - Female
KW - Humans
KW - Infusions, Intravenous
KW - Male
KW - Middle Aged
KW - Middle Cerebral Artery
KW - Migraine Disorders
KW - Reference Values
KW - Regional Blood Flow
KW - Tomography, Emission-Computed, Single-Photon
KW - Ultrasonography, Doppler, Transcranial
KW - Vascular Headaches
M3 - Journal article
C2 - 11993614
VL - 22
SP - 54
EP - 61
JO - Cephalalgia
JF - Cephalalgia
SN - 0800-1952
IS - 1
ER -
ID: 128983613